Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer

被引:108
作者
Hanagiri, Takeshi [1 ]
Sugaya, Masakazu [1 ]
Takenaka, Masaru [1 ]
Oka, Sohich [1 ]
Baba, Tetsuro [1 ]
Shigematsu, Yoshiki [1 ]
Nagata, Yoshika [1 ]
Shimokawa, Hidehiko [1 ]
Uramoto, Hidetaka [1 ]
Takenoyama, Mitsuhiro [1 ]
Yasumoto, Kosei [1 ]
Tanaka, Fumihiro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan
关键词
CYFRA; 21-1; CEA; Surgical resection; Non-small cell lung cancer; Postoperative prognosis; VINORELBINE PLUS CISPLATIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA ANTIGEN; TUMOR-MARKER; SERUM; SCC; ASSOCIATION; RECURRENCE; EXPRESSION; SURVIVAL;
D O I
10.1016/j.lungcan.2011.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Subjects: This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008. Results: The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19-88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p < 0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213-5.442, p = 0.014). Conclusion: A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:112 / 117
页数:6
相关论文
共 34 条
  • [1] [Anonymous], 1999, HISTOLOGICAL TYPE LU
  • [2] Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer
    Blankenburg, Florian
    Hatz, Rudolf
    Nagel, Dorothea
    Ankerst, Donna
    Reinmiedl, Judith
    Gruber, Christine
    Seidel, Dietrich
    Stieber, Petra
    [J]. TUMOR BIOLOGY, 2008, 29 (04) : 272 - 277
  • [3] Positron emission tomography and improved survival in patients with lung cancer - The Will Rogers phenomenon revisited
    Chee, Karen G.
    Nguyen, Danh V.
    Brown, Monica
    Gandara, David R.
    Wun, Ted
    Lara, Primo N., Jr.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (14) : 1541 - 1549
  • [4] CEA IN TUMORS OF OTHER THAN COLORECTAL ORIGIN
    CHEVINSKY, AH
    [J]. SEMINARS IN SURGICAL ONCOLOGY, 1991, 7 (03): : 162 - 166
  • [5] Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer
    Diez, M
    Torres, A
    Maestro, ML
    Ortega, MD
    Gomez, A
    Pollan, M
    Lopez, JA
    Picardo, A
    Hernando, F
    Balibrea, JL
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (10) : 1248 - 1254
  • [6] Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial
    Douillard, Jean-Yves
    Rosell, Rafael
    De Lena, Mario
    Carpagnano, Francesco
    Ramlau, Rodryg
    Gonzales-Larriba, Jose Luis
    Grodzki, Tornasz
    Pereira, Jose Rodrigues
    Le Groumellec, Alain
    Lorusso, Vito
    Clary, Claude
    Torres, Antonio J.
    Dahabreh, Jabrail
    Souquet, Pierre-Jean
    Astudillo, Julio
    Fournel, Pierre
    Artal-Cortes, Angel
    Jassem, Jacek
    Koubkova, Leona
    His, Patricia
    Riggi, Marcella
    Hurteloup, Patrick
    [J]. LANCET ONCOLOGY, 2006, 7 (09) : 719 - 727
  • [7] Estimates of the cancer incidence and mortality in Europe in 2006
    Ferlay, J.
    Autier, P.
    Boniol, M.
    Heanue, M.
    Colombet, M.
    Boyle, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 581 - 592
  • [8] DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES
    GOLD, P
    FREEDMAN, SO
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) : 439 - +
  • [9] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714
  • [10] Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study
    Goya, T
    Asamura, H
    Yoshimura, H
    Kato, H
    Shimokata, K
    Tsuchiya, R
    Sohara, Y
    Miya, T
    Miyaoka, E
    [J]. LUNG CANCER, 2005, 50 (02) : 227 - 234